Quince Therapeutics, Inc. (NASDAQ:QNCX) Financings

Quince Therapeutics, Inc.

Financings

RaiseDate
Private placement of series C non-voting convertible preferred stock and warrants
Closed: US$115M raised · warrants that could bring up to an additional $83 million upon exercise (including…
Aug 14, 2026
Private placement of shares of common stock (or pre-funded warrants) and accompanying common warrants
Closed: US$11.5M raised · US$1.325 a share · Warrants at US$1.2 for 60 months · Citizens Capital Markets +2
Dealers: Citizens Capital Markets (lead), Maxim Group LLC, Brookline Capital Markets
Buyers: Nantahala Capital (led the private placement); ADAR1 Capital Management; Quince senior management
Insiders: Members of Quince's senior management participated
Use of proceeds: Working capital and general corporate purposes, including Phase 3 NEAT trial enrollment in A-T, R&D, G&A and capital expenditures
Jun 18, 2025

Read by 6ix AI from the company's releases